Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.23.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Total revenue $ 1,561 $ 606
Costs of revenue 265 449
Gross profit 1,296 157
Operating expenses:    
Research and development 6,450 5,886
General and administrative 3,990 3,603
Sales and marketing 1,336 1,288
Grant and contract expenses 855
Total operating expenses 12,631 10,777
Loss from operations (11,335) (10,620)
Other income (expenses):    
Interest expense (17) (25)
Interest income 23 101
Forgiveness of PPP loan 391
Gain (loss) on the disposal of assets (1) 144
Change in fair value of derivative liabilities (1,091) 696
Other income (expense) 382 4
Total other income (expense), net (704) 1,311
Net loss before income taxes (12,039) (9,309)
Provision for income taxes
Net loss (12,039) (9,309)
Deemed dividend related to beneficial conversion feature on convertible preferred stock (4,450)
Net loss attributable to common stockholders $ (16,489) $ (9,309)
Net loss per share – basic and diluted    
Basic – net loss $ (39.92) $ (37.70)
Basic – deemed dividend and accretion of a discount on conversion of preferred stock (14.75)
Basic – attributable to common stockholders (54.67) (37.70)
Diluted – net loss (46.79) (39.91)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock (14.02)
Diluted – attributable to common stockholders $ (60.81) $ (39.91)
Weighted average common shares outstanding:    
Basic 301,610 246,919
Diluted 317,323 250,701
Product [Member]    
Total revenue $ 601 $ 606
Grant and Contract [Member]    
Total revenue $ 960